Agex therapeutics, inc. (AGE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
REVENUES:
Total revenues

1,855

1,728

1,492

1,461

1,545

1,396

0

0

0

Cost of sales

215

244

345

292

318

364

0

0

0

Gross profit

1,640

1,484

1,147

1,169

1,227

1,032

0

0

0

OPERATING EXPENSES:
Research and development

6,169

5,904

5,958

5,843

5,577

5,830

0

0

0

Acquired in-process research and development

-

-

-

-

-

800

0

0

0

General and administrative

8,103

8,139

8,390

7,450

6,466

5,647

0

0

0

Total operating expenses

-14,272

-14,043

-19,210

-18,155

-19,405

-12,277

0

0

0

Loss from operations

-12,632

-12,559

-13,201

-12,124

-10,816

-11,245

0

0

0

OTHER INCOME/(EXPENSES):
Interest income (expense), net

-35

29

85

116

110

116

0

0

0

Other income (expense), net

0

-

-

-

0

-

-

-

-

Gain on sale of equity method investment in Ascendance

-

-

-

-

-

3,215

0

0

0

Other expense, net

-

-

-

-

-

-

-

-

0

Other income, net

-

-

0

0

-

-

0

0

-

Total other income (expense), net

312

323

414

375

268

3,514

0

0

0

NET LOSS BEFORE INCOME TAXES

-12,320

-12,236

-12,787

-11,749

-10,548

-7,731

0

0

0

Income tax provision

-

148

0

0

0

-

-

-

-

NET LOSS

-12,395

-12,384

-12,917

-11,825

-10,621

-7,731

0

0

0

Net loss attributable to noncontrolling interest

-187

-230

-288

-266

-221

-229

0

0

0

NET LOSS ATTRIBUTABLE TO AGEX

-12,208

-12,154

-12,629

-11,559

-10,400

-7,502

0

0

0

NET LOSS PER COMMON SHARE: BASIC AND DILUTED

-0.08

-0.07

-0.09

-0.08

-0.09

-0.08

-0.06

-0.06

-0.01

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED

37

111,380

37

37,630

36

71,645

35

34,225

33,750

Subscription and Advertisement Revenues [Member]
Total revenues

1,325

1,332

1,274

1,305

1,333

1,227

0

0

0

Grant Revenues [Member]
Total revenues

251

180

0

0

0

-

-

-

-

Other Revenues [Member]
Total revenues

279

216

91

194

0

-

0

0

-